OpenLobby.EU
Explore

Elanco Animal Health Incorporated

Elanco is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.

Lobbying Activity

Meeting with Flavio Facioni (Cabinet of Commissioner Olivér Várhelyi)

1 Jul 2025 · Challenges in the fields of animal health, animal welfare, food safety and livestock

Meeting with Alisa Tiganj (Cabinet of Commissioner Christophe Hansen), Antonella Rossetti (Cabinet of Commissioner Christophe Hansen) and

29 Apr 2025 · Role of animal health sector in contributing to a sustainable livestock sector in the EU; Trade and animal health and agricultural policies; Upcoming livestock strategy: content and timeline; Digitalisation in support of farmers

Meeting with Jessika Van Leeuwen (Member of the European Parliament)

26 Mar 2025 · Exchange of views

Response to Improving access to and availability, sharing and re-use of chemical data for the purpose of chemical safety assessments

16 Aug 2022

Elanco Animal Health welcomes the EU initiative towards a better access to chemicals data for safety assessment through simplification and reduction of administrative burden, while helping to minimize duplication of effort in data generation. In particular we support initiatives to compile publicly available information and assessments in a single resource. We note that the primary aim is to better streamline the flow of data on chemicals between different sector authorities (EU (European Union) and national). Elanco welcomes in general initiatives aiming to harmonise rules. Nevertheless, we note such initiatives often raise the overall cost and impact by harmonising to the highest common denominator without taking into account the impact on a commercial enterprise. The key points we would like to emphasise in this consultation are: 1. Investment in R&D (Research & Development) and innovation in the EU must be supported, to avoid disincentives to investment through by allowing lower market entry costs to commercial competitors without compensating innovators. 2. To support investment in R&D and innovation in the EU, trade secret protection law, intellectual property rights and regulatory data protection must not be undermined. The important monetary value of both new data and legacy data must be recognized. 3. The transparency of data is important, but it is critical that the information contains appropriate context to avoid misinterpretation and misuse of data, and that confidential data is not made public which could negatively impact innovation. The EFSA (European Food Safety Authority) Transparency Regulation is not a model to follow because the application data file is disclosed to a wider public prior to product approval, deterring companies from launching products in the EU first. 4. It is important to rigorously pursue the EC objectives through better regulation initiatives to reduce the administrative burden on EU business and agencies. This initiative appears to propose additional reporting and notification requirements, yet it claims not to increase the administrative burden. 5. The EU must bring efficiencies through harmonisation of rules, while respecting better regulation principles (meeting regulatory aims through measures that least impact commercial enterprise) and not taking the path of least resistance by adopting the highest common denominator without solid justification. 6. The need to respect better regulation principles through impact assessments; this initiative highly likely will have significant impacts on business in the EU, and the statements to the contrary in the ‘Call for evidence’ need to be fully substantiated with evidence. Consequently, we urge the Commission to invest more time to evaluate the impact and long-term consequences of this horizontal legislative initiative on access to data together with stakeholders.
Read full response

Meeting with Dermot Ryan (Cabinet of Commissioner Phil Hogan)

5 Dec 2018 · poultry production regulations